Trust & governance
About Microdose GLP One
Released: · Last reviewed:
Our mission, scope, and what we do and do not do.
Microdose GLP One is an affiliate-supported consumer resource that defines the poorly-standardized topic of GLP-1 microdosing, separates marketing terminology from medical evidence, normalizes provider costs, verifies pharmacies, and states what remains unknown. It does not sell medication, prescribe, or recommend a dose.
Mission
We help U.S. consumers understand GLP-1 microdosing and lower-dose strategies accurately. The wellness market uses 'microdose' loosely; we hold a definition firewall that names the exact dose concept on every page and refuses to publish universal dosing schedules.
Scope
We cover semaglutide and tirzepatide microdosing, lower-dose and maintenance strategies, off-ramping, providers, compounded formulations, cost, safety, pharmacy verification, and the clinical research. We separate FDA-approved products from compounded products throughout.
What we do not do
We do not sell or prescribe medication, recommend a dose, provide a syringe-unit calculator or titration chart, or claim a lower dose is safer or equally effective without exact evidence. Provider reviews show their verification status, and every price shows where and when we read it.
Contact and corrections
Reach us through the contact page; report errors via the corrections policy.
Who works on it
Pages are researched and written by Dr. Parmis, a medical researcher (Western University of Health Sciences), and medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). The site is affiliate-supported; see ownership and funding.
Frequently asked questions
Is Microdose GLP One a medical provider?
No. It is a publication, not a healthcare provider, pharmacy, or regulator, and not a substitute for professional medical advice.
Do you sell medication?
No. We publish research and comparisons and do not sell, prescribe, or dispense medication.
Publisher: Microdose GLP One. Compounded medications are not FDA approved. Questions or corrections: see the corrections policy and contact page.